Tempest therapeutics how to#

It was, you know, everybody was courting you again.

Very different proteomics was we had a tiger by the tail. I've been fortunate enough to have two key experiences there with two different companies.

Tempest therapeutics how to#

We were acquired and that was the first M&A cell site deal where I was sitting in the chair and how to run the deal. And you can have the most amazing, you could be a unicorn back then and you were not going public. We were private this you'll remember this is oh, 789 when there were tumbleweed rolling around there, Austin. And so great experience worked there for years, got started to get involved in corporate communications back then.Īnd another interesting thing all the way back to being the lawyer is even when you're young and you're getting right out of school, you're in the boardrooms, right? So you're seeing and hearing the board and senior management side from very early on when you can add nothing in those meetings, but you're actually beginning to learn about what goes on behind the curtain, which obviously is relevant for the job I have now and so stayed in operations and then primarily in oncology, came back to California, worked at proteomics, which is a proteasome inhibition company. We need you to go out and actually drum up deals and revenue as well. I was hired back then into this hybrid legal BD role because I had the legal training, but being a banker and having done a lot of deals, they said, you know, come in and sit, you know, straddle this fence, right? Because it's not. And that was the beginning of the operational role was really getting in. I left banking and went into a company which used to be called Lexicon Genetics, now called Lexicon Pharmaceuticals. I cared about how the companies were building. You're working with really hard working right people and the deal flow you get you do see a lot in a very short amount of time. And so being a banker and a lawyer, it was wonderful from an experience perspective, right? And of course, at the time, you're in your twenties and you're thinking, No, I really need this job right now. You get a ton of experience, but the people walking away, leaving the dinner, we're walking away with the results of the deal, right? And so there was I remember one of my bosses back at Mofo said, You're not long for this job because you care too much about why our clients do things and not how our clients do it right. Yeah, it was right around 2000, and there was a little bit of a pattern in all the closing dinners for the deals, which was I was jealous of the management teams, right? I'm a Californian, came back to California after graduating from NYU, did the big firm Morrison and force their lawyer piece and then was recruited out to be an investment banker on one of the deals I was working on by one of the banks, Lazard. So I actually started out as a corporate finance attorney while I was in grad school in New York and at Merck. So if you give me a little background and context on your background and kind of how you landed attempt, this would be fantastic. I know you have an extensive background, a lot of experience in the biotech industry, with a number of different various roles eventually resulting in the CEO position. I know Tempest went public early 2021 via the reverse merger with Melindo. Jason Robinson: Of course, and just some background context for our viewers. Tempest trades on the Nasdaq under the ticker symbol TPST and Steve, welcome, and thanks for joining us. Tempest is a clinical stage biotech company focusing on developing first in class small molecule therapeutics to treat cancer through mechanisms that directly kill tumors, tumor cells and activate tumor specific immunity. Today I'm joined by Steve Brady, CEO of Tempest Therapeutics. Jason Robinson: Welcome to Seeking Alpha CEO interviews. We encourage you to listen to the video, embedded above, if you need any clarification. Please note that transcription may not be perfect. Leveraging immune system with different opportunities. 27:00 - Roche ( OTCQX:RHHBY) partnership licensing and M&A.18:00 - Clinical studies and data updates.12:30 - Hematological malignancies, solid tumors and treating unmet needs.1:40 - Steve left life as a banker and lawyer on his way to becoming Tempest's ( NASDAQ: TPST) CEO.